Iambic Therapeutics, Inc. (IAM) has 15 SEC Form 4 insider filings on record in the last 90 days. Most recent filing: Oct. 19, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Oct. 19, 2026 filed Oct. 16, 2026 | Catalio Capital Management, LP 10% Owner | $0 | 8,393,170 | — | No | |
|
|
||||||
| Oct. 19, 2026 filed Oct. 16, 2026 | Vogelstein R Jacob Director | $0 | 8,393,170 | — | No | |
|
|
||||||
| Oct. 19, 2026 filed Oct. 16, 2026 | Secora Michael CFO & Chief Corp Dev Ofcr | $0 | 122,684 | — | No | |
|
|
||||||
Pro shows who is buying and selling IAM, and how much:
Free for 7 days, then $4.99/month or $49.90/year. Cancel anytime during the trial and you won't be charged.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
This page shows insider buys 72 hours after they're filed. Pro subscribers get them instantly.
$4.99/month or $49.90/year. Free plan available. Cancel anytime.